DNA Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -207.93% compared to Ginkgo Bioworks Holdings, Inc.'s net margin of -116.82%. Ginkgo Bioworks Holdings, Inc.'s return on equity of -50.92% beat Agenus, Inc.'s return on equity of --.

Ginkgo Bioworks Holdings, Inc. has a consensus price target of $10.00, signalling downside risk potential of -0.99%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 319.5%. Given that Agenus, Inc. has higher upside potential than Ginkgo Bioworks Holdings, Inc., analysts believe Agenus, Inc. is more attractive than Ginkgo Bioworks Holdings, Inc..

Ginkgo Bioworks Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.

Ginkgo Bioworks Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ginkgo Bioworks Holdings, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

Ginkgo Bioworks Holdings, Inc. quarterly revenues are $38.8M, which are larger than Agenus, Inc. quarterly revenues of $30.2M. Ginkgo Bioworks Holdings, Inc.'s net income of -$80.8M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Ginkgo Bioworks Holdings, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings, Inc. is 3.06x versus 0.74x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -207.93% compared to Ginkgo Bioworks Holdings, Inc.'s net margin of 20.83%. Ginkgo Bioworks Holdings, Inc.'s return on equity of -50.92% beat Johnson & Johnson's return on equity of 33.27%.

Ginkgo Bioworks Holdings, Inc. has a consensus price target of $10.00, signalling downside risk potential of -0.99%. On the other hand Johnson & Johnson has an analysts' consensus of $230.63 which suggests that it could fall by -3.9%. Given that Johnson & Johnson has more downside risk than Ginkgo Bioworks Holdings, Inc., analysts believe Ginkgo Bioworks Holdings, Inc. is more attractive than Johnson & Johnson.

Ginkgo Bioworks Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Ginkgo Bioworks Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.14% to investors and pays a quarterly dividend of $1.30 per share. Ginkgo Bioworks Holdings, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ginkgo Bioworks Holdings, Inc. quarterly revenues are $38.8M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Ginkgo Bioworks Holdings, Inc.'s net income of -$80.8M is lower than Johnson & Johnson's net income of $5.1B. Notably, Ginkgo Bioworks Holdings, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 21.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings, Inc. is 3.06x versus 6.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -207.93% compared to Ginkgo Bioworks Holdings, Inc.'s net margin of 34.4%. Ginkgo Bioworks Holdings, Inc.'s return on equity of -50.92% beat Eli Lilly & Co.'s return on equity of 106.26%.

Ginkgo Bioworks Holdings, Inc. has a consensus price target of $10.00, signalling downside risk potential of -0.99%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,183.22 which suggests that it could grow by 11.82%. Given that Eli Lilly & Co. has higher upside potential than Ginkgo Bioworks Holdings, Inc., analysts believe Eli Lilly & Co. is more attractive than Ginkgo Bioworks Holdings, Inc..

Ginkgo Bioworks Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Ginkgo Bioworks Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.57% to investors and pays a quarterly dividend of $1.50 per share. Ginkgo Bioworks Holdings, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ginkgo Bioworks Holdings, Inc. quarterly revenues are $38.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Ginkgo Bioworks Holdings, Inc.'s net income of -$80.8M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Ginkgo Bioworks Holdings, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 46.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings, Inc. is 3.06x versus 14.60x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Zenas BioPharma, Inc. has a net margin of -207.93% compared to Ginkgo Bioworks Holdings, Inc.'s net margin of -335.73%. Ginkgo Bioworks Holdings, Inc.'s return on equity of -50.92% beat Zenas BioPharma, Inc.'s return on equity of -68.2%.

Ginkgo Bioworks Holdings, Inc. has a consensus price target of $10.00, signalling downside risk potential of -0.99%. On the other hand Zenas BioPharma, Inc. has an analysts' consensus of $40.75 which suggests that it could grow by 86.93%. Given that Zenas BioPharma, Inc. has higher upside potential than Ginkgo Bioworks Holdings, Inc., analysts believe Zenas BioPharma, Inc. is more attractive than Ginkgo Bioworks Holdings, Inc..

Ginkgo Bioworks Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zenas BioPharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ginkgo Bioworks Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zenas BioPharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ginkgo Bioworks Holdings, Inc. pays -- of its earnings as a dividend. Zenas BioPharma, Inc. pays out -- of its earnings as a dividend.

Ginkgo Bioworks Holdings, Inc. quarterly revenues are $38.8M, which are larger than Zenas BioPharma, Inc. quarterly revenues of --. Ginkgo Bioworks Holdings, Inc.'s net income of -$80.8M is lower than Zenas BioPharma, Inc.'s net income of -$51.5M. Notably, Ginkgo Bioworks Holdings, Inc.'s price-to-earnings ratio is -- while Zenas BioPharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings, Inc. is 3.06x versus 60.90x for Zenas BioPharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.